ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy

Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma that harbors tumor-promoting properties. No good biomarkers exist to monitor the effect of stromal targeting therapies or to predict response. We set out to identify such non-invasive markers for PDAC stroma and predict resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Veenstra, V. L., Damhofer, H., Waasdorp, C., van Rijssen, L. B., van de Vijver, M. J., Dijk, F., Wilmink, H. W., Besselink, M. G., Busch, O. R., Chang, D. K., Bailey, P. J., Biankin, A. V., Kocher, H. M., Medema, J. P., Li, J. S., Jiang, R., Pierce, D. W., van Laarhoven, H. W. M., Bijlsma, M. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237826/
https://www.ncbi.nlm.nih.gov/pubmed/30442938
http://dx.doi.org/10.1038/s41389-018-0096-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237826/
https://www.ncbi.nlm.nih.gov/pubmed/30442938
http://dx.doi.org/10.1038/s41389-018-0096-9

Ejemplares similares